TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Stock
Certificat
DE000SD7S5N5
| Market Closed - Deutsche Boerse AG 15:46:45 2024-05-31 EDT | ||
| 18.04 EUR | +0.89% |
|
| Current month | +4.52% | ||
| 1 month | +4.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 18.04 | +0.89% |
| 24-05-30 | 17.88 | +0.28% |
| 24-05-29 | 17.83 | -0.22% |
| 24-05-28 | 17.87 | -0.83% |
| 24-05-27 | 18.02 | -1.58% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 03:46 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SD7S5N |
| ISIN | DE000SD7S5N5 |
| Date issued | 2021-04-28 |
| Strike | 253.6 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.66 € |
|---|---|
| Lowest since issue | 0.035 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
